Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LXRX vs AQST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LXRX Captures Overall Composite Edge (48.7 HOLD vs 62.9 BUY), While AQST Leads 3–2 on Growth & Valuation Pillars

LXRX Overall Winner 6-Pillar Tally: LXRX 2 – 3 AQST (1 Tie) Matrix Metrics: LXRX 4 – 4 AQST

As of Nov 20, 2026, Lexicon Pharmaceuticals, Inc. (LXRX) captures the overall head-to-head institutional edge over Aquestive Therapeutics, Inc. (AQST) on higher Unified Composite conviction (48.7/100 HOLD vs. 62.9/100 BUY) after splitting the core matrix 4–4 (led by Growth & Scale, Options & Positioning), while AQST wins 3–2 across the 6-pillar growth and valuation breakdown. LXRX trades at $1.53 (N/M Forward P/E, -147.4% operating margin) versus AQST at $3.46 (N/M Forward P/E, -114.1% operating margin).

  • Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. LXRX 48.7/100 HOLD), LXRX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-147.4% vs. -114.1% operating margin) and revenue trajectory (-20.7% vs. -41.0% YoY).
  • Technical & Structure Timing Caution: LXRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.7); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LXRX vs AQST
LXRX NASDAQ Head-to-Head Winner
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Preparations
$1.53
-8.38% 1D
Market Cap $743.5M
TTM Revenue $39M
Forward P/E N/M
Beta / 30D Vol 0.85β · 69% Vol
Unified Composite Score
48.7 / 100 HOLD
Tech 25.0 Fund 49.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.6%), weak momentum, RSI 39
RSI-14: 38.7 · SMA20: $1.63 · SMA50: $1.73
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.89β · 56% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 36
RSI-14: 36.5 · SMA20: $3.77 · SMA50: $4.23

6-Pillar Scorecard Institutional Category Breakdown (LXRX 2 – 3 AQST)

Columns: Metric · LXRX · AQST
1. Valuation Multiples AQST
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 19.5x 8.9x
2. Growth & Scale LXRX
Revenue Growth (YoY) -20.7% -41.0%
Earnings Growth (YoY) -63.4% +0.0%
TTM Revenue (USD) $39M $49M
Market Cap $743.5M $465.7M
3. Profitability & Quality AQST
Gross Margin 91.4% 65.3%
Operating Margin -147.4% -114.1%
Net Profit Margin -161.8% -162.3%
Return on Equity (ROE) -43.9% 0.0%
4. Balance Sheet & Cash Flow AQST
Cash Generation (TTM) -$49M -$41M
Cash Flow Margin N/A -83.3%
Net Cash / Leverage $9.5M Net Debt (0.33x D/E) $32M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LXRX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 556.1% (59th %ile) 87.9% (64th %ile)
Put/Call OI Skew 0.13x (Call-Skewed) 0.98x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LXRX (4) vs AQST (4)
Institutional Metric LXRX AQST Criterion Row Edge
Market Capitalization
Scale
$743.5M $465.7M Larger Scale LXRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-20.7% -41.0% Higher Growth LXRX
Operating Margin (TTM)
Profitability
-147.4% -114.1% Higher Margin AQST
Net Profit Margin
Profitability
-161.8% -162.3% Higher Margin LXRX
Return on Equity (ROE)
Capital Efficiency
-43.9% 0.0% Higher ROE AQST
52-Week Range Position
Momentum
27% ($1–$3) 14% ($3–$7) Stronger Trend LXRX
Beta / 30D Volatility
Risk Regime
0.85β · 69% Vol 0.89β · 56% Vol Lower Realized Risk AQST
Unified Institutional Score
Composite Signal
48.7 / 100 (HOLD) 62.9 / 100 (BUY) Higher Composite AQST
Trailing 12M Revenue (USD)
Operating Scale
$39M $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
91.4% 65.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 19.5x EV/Rev N/M PEG · 8.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$49M ($9.5M Net Debt (0.33x D/E)) -$41M ($32M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LXRX +18.9 pp
LXRX: +2.68% · AQST: -16.22%
3M Horizon AQST +6.13 pp
LXRX: -34.05% · AQST: -27.92%
6M Horizon AQST +13.15 pp
LXRX: -29.17% · AQST: -16.02%
1Y Horizon LXRX +46.17 pp
LXRX: +5.52% · AQST: -40.65%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LXRX Revenue AQST Revenue LXRX Op. Margin AQST Op. Margin Margin Leader
FY2018 $30M $70M -388.5% -72.6% AQST
FY2019 $30M $50M 437.5% -100.1% LXRX
FY2020 $20M $50M -204.2% -93.6% AQST
FY2021 N/A $50M N/A -68.2% AQST
FY2022 N/A $50M N/A -88.2% AQST
FY2023 $0M $50M -15473.0% -29.9% AQST
FY2024 $10M $60M -3284.7% -53.5% AQST
FY2025 $50M $40M -98.2% -159.5% LXRX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LXRX BREAKDOWN
102d in phase · OBV NEUTRAL
Current IV 556.1%
IV Percentile 59th %ile
Put/Call OI Skew 0.13x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LXRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AQST BREAKDOWN
61d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 64th %ile
Put/Call OI Skew 0.98x (Balanced)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LXRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $743.5M market capitalization and -147.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $465.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LXRX vs AQST Key Questions & Quantitative Answers

As of Nov 20, 2026, Lexicon Pharmaceuticals, Inc. (LXRX) captures the overall head-to-head institutional edge over Aquestive Therapeutics, Inc. (AQST) on higher Unified Composite conviction (48.7/100 HOLD vs. 62.9/100 BUY) after splitting the core matrix 4–4 (led by Growth & Scale, Options & Positioning), while AQST wins 3–2 across the 6-pillar growth and valuation breakdown. LXRX trades at $1.53 (N/M Forward P/E, -147.4% operating margin) versus AQST at $3.46 (N/M Forward P/E, -114.1% operating margin). Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. LXRX 48.7/100 HOLD), LXRX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-147.4% vs. -114.1% operating margin) and revenue trajectory (-20.7% vs. -41.0% YoY). Technical & Structure Timing Caution: LXRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.7); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LXRX leads the Growth & Scale pillar: LXRX posts -20.7% YoY revenue growth and -63.4% YoY earnings growth on $39M TTM revenue (91.4% gross margin, -147.4% operating margin), compared with AQST at -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LXRX cumulative revenue shifted +66.7% while AQST shifted -42.9%. In operating R&D and SG&A reinvestment, LXRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AQST.

AQST screens cheaper on headline valuation multiples. LXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 19.5x EV/Revenue (unreported FCF margin), whereas AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LXRX (-43.9% ROE) versus AQST (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, LXRX carries 556.1% implied volatility (59th %ile, Balanced (25th–60th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.85β · 69% Vol realized risk). By comparison, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.